Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder

被引:179
作者
Schloesser, Robert J.
Huang, Jian
Klein, Peter S.
Manji, Husseini K.
机构
[1] NIMH, NIH, Lab Mol Pathophysiol Mood Anxiety & Disorders Pro, Bethesda, MD 20892 USA
[2] Univ Penn, Sch Med, Dept Med Hematol Oncol, Philadelphia, PA USA
关键词
bipolar disorder; neuroplasticity; intracellular signaling cascades; lithium; valproic acid; mood stabilizer;
D O I
10.1038/sj.npp.1301575
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Bipolar disorder ( BPD) is characterized by recurrent episodes of disturbed affect including mania and depression as well as changes in psychovegetative function, cognitive performance, and general health. A growing body of data suggests that BPD arises from abnormalities in synaptic and neuronal plasticity cascades, leading to aberrant information processing in critical synapses and circuits. Thus, these illnesses can best be conceptualized as genetically influenced disorders of synapses and circuits rather than simply as deficits or excesses in individual neurotransmitters. In addition, commonly used mood-stabilizing drugs that are effective in treating BPD have been shown to target intracellular signaling pathways that control synaptic plasticity and cellular resilience. In this article we draw on clinical, preclinical, neuroimaging, and post-mortem data to discuss the neurobiology of BPD within a conceptual framework while highlighting the role of neuroplasticity in the pathophysiology and treatment of this disorder.
引用
收藏
页码:110 / 133
页数:24
相关论文
共 244 条
  • [81] Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: A role in depression
    Eisch, AJ
    Bolanos, CA
    de Wit, J
    Simonak, RD
    Pudiak, CM
    Barrot, M
    Verhaagen, J
    Nestler, EJ
    [J]. BIOLOGICAL PSYCHIATRY, 2003, 54 (10) : 994 - 1005
  • [82] SODIUM VALPROATE DECREASES EXPLORATORY-BEHAVIOR IN MICE - DEVELOPMENT OF TOLERANCE AND CROSS-TOLERANCE WITH CHLORDIAZEPOXIDE
    FILE, SE
    ARANKO, K
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 151 (02) : 293 - 299
  • [83] A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation
    Frame, S
    Cohen, P
    Biondi, RM
    [J]. MOLECULAR CELL, 2001, 7 (06) : 1321 - 1327
  • [84] The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder
    Frangou, S
    Raymont, V
    Bettany, D
    [J]. BIPOLAR DISORDERS, 2002, 4 (06) : 378 - 385
  • [85] \Magnetic resonance imaging studies in early-onset bipolar disorder: A critical review
    Frazier, JA
    Ahn, MS
    DeJong, S
    Bent, EK
    Breeze, JL
    Giuliano, AJ
    [J]. HARVARD REVIEW OF PSYCHIATRY, 2005, 13 (03) : 125 - 140
  • [86] Goold RG, 1999, J CELL SCI, V112, P3373
  • [87] Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs
    Gould, TD
    Manji, HK
    [J]. NEUROPSYCHOPHARMACOLOGY, 2005, 30 (07) : 1223 - 1237
  • [88] AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test
    Gould, TD
    Einat, H
    Bhat, R
    Manji, HK
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 (04) : 387 - 390
  • [89] In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3
    Gould, TD
    Chen, G
    Manji, HK
    [J]. NEUROPSYCHOPHARMACOLOGY, 2004, 29 (01) : 32 - 38
  • [90] GOULD TD, 2007, NEUROPSYCHOPHAR 0214